Spectrum of Rhabdomyosarcoma in a Tertiary Care Center – A 20 Year Study
Main Article Content
Abstract
Background: Rhabdomyosarcoma (RMS) is a rare tumor. It is the commonest soft tissue tumor in children. It is the third most common extracranial solid tumor in children. Head neck region was the most common sites followed by extremities, orbit, vagina, bladder and etc. Most of the cases are diagnosed in first decade of the life. The commonest histological type is Embryonal Rhabdomyosarcoma (E RMS).
Aims and Objectives: The aim of our study was to see the distribution of RMS among children below 18 years of age. To note the distribution of age, sex of the children, site of the tumor, and the histological type of the tumor. It is classified as low, intermediate and high-risk group and the stage of the tumor also determined during presentation.
Materials and Methods: The study was carried out in a Tertiary Care Center over a period of 20 years (2001-2021). We took all the specimens came to the Department of Pathology with Clinical diagnosis of RMS. We then performed the histopathological processing of the specimens by standard technique. We also noted the history, investigations from the specimen request form.
We took the Ethics Committee approval from the Institutional Ethics Committee and took the informed consent from the patients and patient party.
Result and Analysis: There were 123 children in our study. The most common age group was 1-10 years. The most frequent site was Head Neck region. The most frequent histological type was E-RMS.
Conclusion: Early diagnosis, early implementation of management (Surgery, Chemotherapy and etc.) and patients’ awareness are necessary for the better outcome.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Lanier AP, Holck P, Ehrsam Day G, Key C.Childhood cancer among Alaska Natives. Pediatr.2003;112(5)e396.
doi: 10.1542/peds.112.5.e39
II. Gupta V, Kalraiya A, Mekle D. Spectrum of pediatric malignancy- A cancer hospital-based study. Pediatric Rev Int J Pediatric Res. 2020;7(1):27-31.
III. Sandler A, Reilly K, Widemann B. Editorial: Special issue on rare cancers. Curr Probl Cancer. 2021 Aug;45(4):100774.
doi: 10.1016/j.currproblcancer.2021.100774. Epub 2021 Jul 8. PMID: 34304884;
PMCID: PMC8383746.
IV. Keat N, Law K, McConnell A, Seymour M, Welch J, Trimble T, et al. International Rare Cancers Initiative (IRCI). Ecancermedicalscience. 2013;7:ed20. doi: 10.3332/ ecancer.2013.ed20 [DOI] [PMC free article] [PubMed] [Google Scholar]
V. Shrutha SP, Vinit GB: Rhabdomyosarcoma in a pediatric patient: a rare case report. Contemp Clin Dent. 2015, 6:113-115. 10.4103/0976-237X.1493055.
VI. Haider A, Sunkara V, Basnet S, et al. (September 26, 2023) Navigating Complexities in Pediatric Rhabdomyosarcoma: A Case Report on Its Neurological Implications. Cureus 15(9): e45991. doi:10.7759/cureus.45991
VII. Shern JF, Yohe ME, Khan J. Pediatric Rhabdomyosarcoma. Crit Rev Oncog.2015;20(3-4):227-43. doi: 10.1615/critrevoncog.2015013800. PMID: 26349418; PMCID: PMC5486973.
VIII. Deepak Bansal, Anirban Das, Amita Trehan, Rakesh Kapoor et al., Pediatric Rhabdomyosarcoma in India: A Single-center Experience, Indian Pediatrics, September 15, 2017; 735 – 738
IX. Gianni Bisogno, Meriel Jenney, Christophe Bergeron et al. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial ; The Lancet Oncology, August 2018, 19 (8) pg 1061- 1071
X. Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, Barr FG, Hawkins DS. Rhabdomyosarcoma. Nat Rev Dis Primers. 2019 Jan 7;5(1):1. doi: 10.1038/ s41572-018-0051-2. PMID: 30617281; PMCID: PMC7456566.
XI. Olga Slater , Jennifer E. Gains , Anna M. Kelsey et al. , Localised rhabdomyosarcoma in infants (<12 months) and young children (12–36 months of age) treated on the EpSSG RMS 2005 study; European Journal of Cancer, 2022; vol 160 pg 206-214.
XII. Ferrari A, Casanova M, Bisogno G, Zanetti I, Cecchetto G, De Bernardi B, et al. Rhabdomyosarcoma in infants younger than one year old: a report from the Italian Cooperative Group. Cancer. 2003;97:2597-604
XIII. Sharma, Raghav; Pendharkar, Chinmay Shrikrishna; Singh, Vikram; Venkatesan, Somasundaram. Unmasking rhabdomyosarcoma: Fine-needle aspiration cytology evaluation of hand swelling in a 2-year-old girl. Journal of Diagnostic and Academic Pathology 1(2):p 96-98, Jul–Dec 2024. | DOI: 4103/jdap.jdap_27_24
XIV. Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59:5-10
XV. Womer RB, Barr FG, Linardic CM. Rhabdomyosarcoma. In: Orkin SH, Fisher DE, Ginsburg D, Thomas Look A, Lux SE, Nathan DG. Nathan and Oski’s Hematology and Oncology of Infancy and Childhood. 8th ed. Philadelphia: Elsevier Saunders; 2015. p.1929.
XVI. Martin-Giacalone BA, Weinstein PA, Plon SE, Lupo PJ. Pediatric Rhabdomyosarcoma: Epidemiology and Genetic Susceptibility. J Clin Med. 2021 May 9;10(9):2028. doi: 10.3390/jcm10092028. PMID: 34065162; PMCID: PMC8125975.
XVII. Michał Łomiak, Tomasz Świtaj, Mateusz Spałek, Diagnosis and treatment of rhabdomyosarcomas; Oncol Clin Pract 2023; 19, 4: 250–279
XVIII. Matthew T. McEvoy, David A. Siegel, Shifan Dai, Mehmet Fatih Okcu, Mark Zobeck, Rajkumar Venkatramani, Philip J. Lupo, Pediatric rhabdomyosarcoma incidence and survival in the United States: An assessment of 5656 cases, 2001–2017 ; Cancer Medicine. 2023;12:3644–3656.
XIX. Markiz SN, Khan S, Wagley ZB, et al. Rhabdomyosarcoma in children: Retrospective analysis from a single tertiary care center in Saudi Arabia. Cancer Reports. 2023;6(1):e1683. doi:10.1002/cnr2.1683
XX. Zarrabi, A.; Perrin, D.; Kavoosi, M.; Sommer, M.; Sezen, S.; Mehrbod, P.; Bhushan, B.; Machaj, F.; Rosik, J.; Kawalec, P.; et al. Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies. Cancers 2023, 15, 5269. https://doi.org/10.3390/cancers15215269
XXI. Ruiz-Mesa, C.; Goldberg, J.M.; Coronado Munoz, A.J.; Dumont, S.N.; Trent, J.C. Rhabdomyosarcoma in adults: New perspectives on therapy. Curr. Treat. Options Oncol. 2015, 16, 27. [Google Scholar] [CrossRef]
XXII. Dasgupta, R.; Rodeberg, D.A. Update on rhabdomyosarcoma. Semin. Pediatr. Surg. 2012, 21, 68–78. [Google Scholar] [CrossRef] [PubMed]
XXIII. Haduong JH, Heske CM, Allen-Rhoades W, Xue W, Teot LA, Rodeberg DA, Donaldson SS, Weiss A, Hawkins DS, Venkatramani R. An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatr Blood Cancer. 2022 Apr;69(4):e29511. doi: 10.1002/pbc.29511. Epub 2022 Feb 7. PMID: 35129294; PMCID: PMC8976559
XXIV. Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol. Nov 2013;20(6):387–97. doi: 10.1097/PAP.0b013e3182a92d0d
XXV. Rekhi B, Upadhyay P, Ramteke MP, Dutt A. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes. Mod Pathol. Dec 2016;29(12):1532–1540. doi: 10.1038/ modpathol.2016.144 [DOI] [PMC free article] [PubMed] [Google Scholar]
XXVI. Agaram NP, Chen CL, Zhang L, LaQuaglia MP, Wexler L, Antonescu CR. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis. Genes Chromosomes Cancer. Sep 2014;53(9):779–87. doi: 10.1002/gcc.22187 [DOI] [PMC free article][PubMed] [Google Scholar]
XXVII. Machado I, Mayordomo-Aranda E, Giner F, Llombart-Bosch A. The Role of Immunohistochemistry in Rhabdomyosarcoma Diagnosis Using Tissue Microarray Technology and a Xenograft Model. Fetal Pediatr Pathol. 2015;34(5):271-81. doi: 10.3109/15513815.2015.1042604. Epub 2015 Jun 30. PMID:
XXVIII. Johannes H.M. Merks , Eva Brack, , Martin Ebinger et al. European standard clinical recommendations for children and adolescents with Rhabdomyosarcoma a joint EpSSG, CWS and ERNPaedCan project , EJC Paediatric Oncology 5 (2025) 100229..
XXIX. Rijs, Z.; Jeremiasse, B.; Shifai, N.; Gelderblom, H.; Sier, C.F.; Vahrmeijer, A.L.; van Leeuwen, F.W.; van der Steeg, A.F.; van de Sande, M.A. Introducing fluorescence-guided surgery for pediatric Ewing, osteo-, and rhabdomyosarcomas: A literature review. Biomedicines 2021, 9, 1388. [Google Scholar] [CrossRef]